

Test Report

Qualitative in vitro cytotoxicity MEM elution assay of “Walletmor Payment Implant with Vivokey biopolymer”

Study code: 21-45-1

Report Index: 21-45-1-SP.01

Date of issue: 24.05.2021

The report shall not be reproduced except in full without approval of the laboratory, SOP 05-ZAL05.08, Revised on 12.11.2020

GLP Certificate
24/2019/DPL
Accreditation
No. AB 1763



	TEST REPORT	
	Study Code	21-45-1

1. TYPE AND PURPOSE OF THE TEST

The scope of the study included testing of the cytotoxic properties of the test item carried out in accordance with the principles of ISO 10993-5:2009(E) and ISO 10993-12:2021(E) standards.

The aim of the study was to determine the cytotoxic properties of the test item provided by the Customer.

2. CONSENT OF THE LOCAL ETHICS COMMITTEE

N/A

3. DATES

Experimental starting date: 17.05.2021

Experimental completion date: 21.05.2021

4. ADDRESSES

Customer

Name: Walletmor LTD

Address: 85 Great Portland St, W1W 7LT London, United Kingdom

Test Facility

Name: Konmex sp. z o.o.

Address: ul. Nałkowskiej 5, 05-410 Józefów, Poland

5. PERSONNEL

Study Director

Kamila Gołaszewska

Tel.: +48 514 706 400, Fax: +48 22 780 06 10, e-mail: k.golaszewska@konmex.com

Address: Konmex sp. z o.o., ul. Nałkowskiej 5, 05-410 Józefów, Poland

Study Personnel

Justyna Wierzchowska

Address: Konmex sp. z o.o., ul. Nałkowskiej 5, 05-410 Józefów, Poland

The report shall not be reproduced except in full without approval of the laboratory, SOP 05-ZAL05.08, Revised on 12.11.2020

GLP Certificate
24/2019/DPL
Accreditation
No. AB 1763



6. TEST ITEM

a. Test Item

Table 1. Information on test item.

Name: Walletmor Payment Implant with Vivokey biopolymer		
REF: N/A	LOT: N/A	Item code: 21-45-A
Mfg date: 01.01.2021	Exp date: 01.01.2029	Sterile: EO
Storage conditions: Temperature: normal, Humidity: N/A		
Intended use: N/A		

Information above were submitted by the Customer. Responsibility for assuring proper conditions during transportation of the test items lied with the Customer. Results apply to the samples as received.

Receiving date: 2021-05-06

Storage conditions: Test item was stored at temperature 18-25°C

b. Reference material (if applicable)

N/A

c. Reliability check

Table 2. Information on reliability check.

Negative (K-)	HDPE
Positive (K+)	Latex
Blank (B)	Supplemented MEM

d. Extraction

Table 3. Information on extracts.

No	Extract	Vehicle	Ratio	Time [h]	Temperature [°C]
1.	7 x 21-45-A	Supplemented medium	6 cm ² /mL	72±2	37±1
2.	K+	Supplemented medium	6 cm ² /mL	72±2	37±1
3.	K-	Supplemented medium	0,2 g/mL	72±2	37±1

The report shall not be reproduced except in full without approval of the laboratory, SOP 05-ZAL05.08, Revised on 12.11.2020

	TEST REPORT	
	Study Code	21-45-1
		Page 4 of 7

7. TEST SYSTEM

Description of the test system

Cell line: L929

Passage no.: 26

Culturing: 37±1°C, 5±0,1%,

Medium: MEM supplemented with 10% FBS, 4 mM Glutamax, 100 IU/ml penicillin, 100 µg/ml streptomycin

Before the study, cells were passaged not less than twice after thawing.

Justification of assay system

The evaluation of the cytotoxic potential using MEM elution assay is described by the International Organization for Standardization - ISO: 10993-5:2009 (E), part 5.

Animal identification (if applicable)

N/A

Quarantine (if applicable)

N/A

8. SAMPLE PREPARATION

Before the study, the test item undergone no preparations. According to ISO 10993-12:2021(E), an extract of the test item in culture medium was prepared by immersing the device in the medium and extracted as indicated in Table 3. After extraction the extracts of the controls and test item were clear, with no observable particulates. Extracts were not filtered, centrifuged or otherwise altered and were used immediately after preparation.

9. DESCRIPTION OF TEST METHOD

Triplicate monolayers of L929 cells were dosed with 600 µL of extracts and incubated in the presence of 5±0,1 % CO₂ according to Table 3. Staining solution was prepared, just before use, by mixing Trypan Blue solution with supplemented MEM in 1:1 ratio. Following the incubation, 100 µL of prepared staining solution were dispensed in each well. Afterwards, cytotoxicity was assessed by microscopic observations.

The report shall not be reproduced except in full without approval of the laboratory, SOP 05-ZAL05.08, Revised on 12.11.2020

GLP Certificate
24/2019/DPL
Accreditation
No. AB 1763



10. EQUIPMENT

Table 4. Equipment used in the study.

No	Name	Serial No	Calibration Certificate No
1.	Balance	3536	5128/1446/20
2.	Laminar flow hood	332	085
3.	Incubator	15-17793	02/JK
4.	Water bath	17177	WL54.2020.02
5.	Cell counter	508BR08886	WL46.2021.01
6.	Microscope	1619957-1	N/A
7.	Centrifuge	10251108815	03/JK
8.	Microscope	419098	N/A
9.	Pipetor	N/A	N/A
10.	Pipette 10 µl	LE11810	21-03-02/04651
11.	Pipette 200 µl	MH11356	SW/0101/2021
12.	Pipette 1000 µl	MD10937	SW/0097/2021

11. MATERIALS

Table 5. Materials used in the study.

No.	Name	Manufacturer	REF	LOT
1.	MEM	Gibco	51200-046	2162330
2.	Pen/Strep	Sigma Aldrich	P4458-100ML	0000088375
3.	Glutamax	Gibco	35050-061	2238969
4.	FBS	Gibco	10270-106	2232584
5.	PBS	Gibco	18912-014	2165328
6.	TrypLE Express	Gibco	12604-021	2192947
7.	Trypan Blue Dye	BioRad	1450013	64274014
8.	Trypan Blue	Sigma Aldrich	T8154-100ML	RNBJ4500
9.	HDPE	LG Chem	SM800F7	20141
10.	Latex	Mercator Medical	RC10003085	1906026B185
11.	Line Antybacteria 70	Linegal Chemicals	LL-0001.2	100/W/2020

The report shall not be reproduced except in full without approval of the laboratory, SOP 05-ZAL05.08, Revised on 12.11.2020



12. RESULTS

Cytotoxic potential was assessed based on ISO 10993-5:2009(E), Biological evaluation of medical devices – Part 5: Tests for in vitro cytotoxicity, Table 1 - “Qualitative morphological grading of cytotoxicity of extracts”.

The achievement of a numerical grade 3 or greater is considered as cytotoxic effect.

Acceptance criteria: blank grade < 3

positive control grade \geq 3

negative control grade < 3

test item extract grade < 3

Table 6. Results of cytotoxic potential assessment.

Sample	Grade	
Blank	0	Valid
Negative control	0	Valid
Positive control	4	Valid
Test item	0	No cytotoxic potential

13. DEVIATIONS

No incident that could have affected the quality of the raw data obtained was observed.

14. CONCLUSIONS

On the basis of the results interpreted according to ISO 10993-5:2009(E), the test item “Walletmor Payment Implant with Vivokey biopolymer (REF: N/A, LOT: N/A)” should be considered non-cytotoxic.

15. LIST OF RECORDS AND MATERIALS SUBMITTED TO THE ARCHIVE

- Raw data,
- Study report,
- Laboratory journal,
- Data on monitoring the testing environment - temperature and humidity records at the time of testing.

All the above-mentioned records and documents are to be filed to the archives of the research facility for 10 years after issuing the study report. The Test Facility does not store test items in the archive.

The report shall not be reproduced except in full without approval of the laboratory, SOP 05-ZAL05.08, Revised on 12.11.2020



16. RELATED DOCUMENTS

- United States Food and Drug Administration, Title 21 Code of Federal Regulations Part 58, Federal Register 22nd December 1978 and subsequent amendments,
- ISO 10993-5:2009(E), Biological evaluation of medical devices – Part 5: Tests for in vitro cytotoxicity,
- ISO 10993-12:2021(E), Biological evaluation of medical devices – Part 12: Sample preparation and reference materials.

Study Director	Quality Assurance

The report shall not be reproduced except in full without approval of the laboratory, SOP 05-ZAL05.08, Revised on 12.11.2020

